Health Sector Faces Dynamic Changes Amid FDA Requests and Legislative Shifts
Recent developments in the health sector include Intercept Pharma pulling a liver drug from the U.S. market following FDA's request, China's legislative steps to enhance food safety, and the U.S. FDA's focus on AI mental health devices. Meanwhile, various sectors face legislative, economic, and strategic challenges.
Intercept Pharmaceuticals announced the withdrawal of its liver disease drug, Ocaliva, from the U.S. market at the request of the Food and Drug Administration. This decision marks another challenge for the company following FDA's previous refusal to fully approve the drug due to concerns over liver injury cases.
China's legislative body has recently passed a significant bill aimed at strengthening food safety protocols. As per China Central Television, the updated law will enhance regulatory oversight and impose stiffer penalties for violations, specifically targeting the transportation of key liquid foods and infant formula, effective December 1.
The U.S. FDA is gearing up for a crucial advisory panel meeting in November to evaluate the growing field of AI-powered digital mental health devices. The agency aims to explore the potential of these tools in bridging mental health service gaps while assessing the inherent risks posed by this emerging technology.
(With inputs from agencies.)
ALSO READ
China's Diplomatic Stance: Avoiding Conflict and Sanctions
Indian women's hockey team qualifies for Asia Cup final, faces hosts China in summit clash in Hangzhou on Sunday.
China Launches Anti-Discrimination Investigation into U.S. Chip Policies
Trump Calls for Stricter Tariffs on China and Oil Sanctions on Russia
China Initiates Investigation into U.S. Tech Trade Practices
Google News